导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 31.76% | 75/4773 |
| 近一周 | -2.37% | 1970/5462 |
| 近一月 | -10.44% | 5078/5421 |
| 近一季 | -13.46% | 4008/5209 |
| 近半年 | 25.17% | 88/4920 |
| 近一年 | 40.35% | 102/4366 |
| 近两年 | 207.10% | 69/2954 |
| 近三年 | 132.32% | 42/2253 |
| 成立以来 | 208.06% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.38% 3169/4961 |
111.27% 51/5312 |
- - |
- - |
| 2025 | 45.13% 614/4813 |
3.98% 1013/3635 |
-0.05% 2792/4076 |
50.16% 319/4524 |
-7.00% 3750/4813 |
| 2024 | 25.41% 262/3463 |
-12.24% 2453/2808 |
0.52% 586/3014 |
18.10% 1061/3129 |
20.37% 41/3463 |
| 2023 | -2.23% 565/2656 |
18.92% 155/2280 |
-8.65% 2008/2385 |
-9.48% 1833/2515 |
-0.57% 226/2655 |
| 2022 | -36.78% 1742/2207 |
-21.40% 1619/1919 |
-0.90% 1658/2016 |
-19.17% 1758/2113 |
0.40% 1498/2208 |
| 2021 | 24.31% 122/1822 |
-14.67% 1181/1255 |
49.31% 1/1330 |
-6.20% 906/1466 |
4.03% 374/1822 |
| 2020 | 45.83% 217/1250 |
10.56% 18/1028 |
29.71% 70/1067 |
-4.15% 1101/1164 |
6.08% 767/1184 |
| 2019 | - - |
- - |
- - |
19.46% 9/850 |
19.52% 6/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 国联安中证半导体ETF VS. 长安沪深300非周期A(740101) |